يعرض 1 - 20 نتائج من 148 نتيجة بحث عن '(( ct ((largest decrease) OR (marked decrease)) ) OR ( 6 026 decrease ))', وقت الاستعلام: 0.42s تنقيح النتائج
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6

    Data Sheet 1_Empagliflozin’s cardioenergetic protective effects through PPARα pathway modulation in heart failure.pdf حسب Hua Wei (60877)

    منشور في 2025
    "…Post-treatment, MRGlu and glucose uptake decreased markedly in the empagliflozin (EMPG) group, while no significant changes were observed in the fenofibrate (FF) group. …"
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14

    Baseline demographic characteristics. حسب Jung-Tae Kim (8997767)

    منشور في 2025
    "…Group 2 exhibited a significantly greater decrease in GCC thickness compared with Group 1(P = 0.026).…"
  15. 15
  16. 16

    (A-H). Case 1: primary subcutaneous facial alveolar echinococcosis. حسب Louis Bohard (22250661)

    منشور في 2025
    "…<p><b>(A)</b> Left frontal swelling at diagnosis. <b>(B)</b> Marked regression of the lesion after 6 months of albendazole therapy. …"
  17. 17
  18. 18

    Time course of best-corrected visual acuity (BCVA) in recurrence and non-recurrence groups. حسب Yasuyuki Sotani (20114144)

    منشور في 2025
    "…<p>In the recurrence group, BCVA (logMAR ± standard deviation) showed no significant change from baselines (0.37 ± 0.20) to 0.35 ± 0.23, 0.35 ± 0.18, 0.31 ± 0.23, 0.34 ± 0.26, 0.28 ± 0.30, and 0.24 ± 0.23 at 1, 3, 6, 12, 24, and 36 months, respectively (Kruskal–Wallis test, P = 0.45). …"
  19. 19

    Annual number of outpatient visits in all eyes. حسب Yasuyuki Sotani (20114144)

    منشور في 2025
    "…In the recurrence group, BCVA (logMAR) showed no significant improvement over time: 0.37 ± 0.20 preoperatively and 0.35 ± 0.23, 0.35 ± 0.18, 0.31 ± 0.23, 0.34 ± 0.26, 0.28 ± 0.30, and 0.24 ± 0.23 at 1, 3, 6, 12, 24, and 36 months, respectively (Kruskal-Wallis test, p = 0.45). …"
  20. 20